A second peer-reviewed real-world analysis published in the American Journal of Audiology confirms Lenire’s effectiveness for tinnitus patients. The study analyzed 140 tinnitus patients treated at New York Hearing Doctors between May 1, 2023, and January 19, 2024. After six weeks of treatment, 72.6% of patients with bothersome tinnitus had a clinically meaningful reduction in tinnitus. After 12 weeks, 81.8% had achieved clinically meaningful reduction, with a mean reduction of 23.8 points on the Tinnitus Handicap Inventory (THI)—greater than three times the threshold for clinically significant reduction. The majority reported they were no longer severely impacted by their tinnitus following 12 weeks of treatment.
Lenire is the only FDA-approved tinnitus treatment device of its kind and uses bimodal neuromodulation—simultaneous stimulation of two nerves for therapeutic purposes. Patients typically use the device at home for two 30-minute sessions daily for approximately 12 weeks under the care of an audiologist with tinnitus expertise. The device plays audio tones via headphones while delivering mild energy pulses to the surface of the tongue.
This evidence is consistent with the first real-world analysis published in Nature Communications Medicine, which showed that 91.5% of U.S. patients treated with Lenire had a clinically significant reduction after 12 weeks. The consistency between real-world outcomes and large-scale clinical trials demonstrates replicability and scalability. Tinnitus affects an estimated 25 million American adults, with approximately 2.5 million in New York alone. Lenire is also available as a treatment option through the US Department of Veterans Affairs, and is the most prevalent service-connected disability compensated by the VA, with more than 3.2 million veterans compensated in 2024.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110750759/Lenire-Shows-Consistent-Positive-Results-For-US-Tinnitus-Patients-In-2Nd-Peer-Reviewed-Real-World-Study